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Taiwan is a hyperendemic area of liver diseases.1
Chronic liver disease and cirrhosis was the sixth
leading cause of death in Taiwan in 2002. Cancer
was the leading cause of death in Taiwan, and
hepatocellular carcinoma (HCC) was the leading
cause of death among all cancers in 2002.2
Hepatitis B virus (HBV) and hepatitis C virus
(HCV) are the two major etiologies of liver dis-
eases in Taiwan.3
Around 15–20% of adults in Taiwan are chron-
ically infected with HBV.4 Most chronic carriage
of HBV results from infection in early childhood,
especially before 2 years of age.5–7 To control
HBV infection, universal HBV immunization was
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started in Taiwan in 1984,8 which significantly de-
creased the HBV carrier and infection rates among
children and adolescents born after the start of
the program. The prevalence of hepatitis B surface
antigen (HBsAg) among persons younger than
15 years of age decreased from 9.8% in 1984 to
0.7% in 1999.9 In addition, the incidence of HCC
in children has declined.10
In studies reported from 1991 and 1993, the
prevalence of antibody to HCV (anti-HCV) in the
general population ranged from 0.4–2.5%.1,11–13
Other studies reported over the period from
1992 to 2003 revealed geographical variations in
the seroprevalence of anti-HCV as well as several
HCV hyperendemic areas. The seroprevalence of
anti-HCV varied from 1.7% to 57.9% in different
townships in these studies.14–19
The Liver Disease Prevention and Treatment
Research Foundation in Taiwan, founded in
1994, initiated screening programs in 1996. As
of May 2005, around 160,000 screenings have
been performed. The aim of this study was to 
investigate the seroprevalence of HBV and HCV
in Taiwan based on the screening data of the
Liver Disease Prevention and Treatment Research
Foundation.
Methods
Screening program
The Liver Disease Prevention and Treatment
Research Foundation initiated an outreach 
community-based screening program for liver dis-
eases in 1996. These screenings were open to the
general population aged ≥ 18 years. Subjects were
invited by mail, radio broadcasts, newspapers and
television to go to the screening station. General
information, including name, sex, and contact in-
formation (including telephone number and ad-
dress) were recorded. Blood samples were obtained
from subjects and sent for aspartate aminotrans-
ferase (AST), alanine aminotransferase (ALT),
HBsAg, anti-HCV and α-fetoprotein (AFP) tests
(General Biologicals Corporation, Hsinchu,
Taiwan). Since most people born after 1984 had
received HBV vaccination, those subjects were not
included in the analysis.
Estimation of patient numbers
To estimate total numbers of HBsAg positive or
anti-HCV positive individuals in Taiwan, the fol-
lowing method based on the combined stratifi-
cations of city/county and age groups was used.
The number of positive individuals in the selected
area (city or county) was calculated according to
age group. The patient number in a selected area
(city or county) = the seropositive rate of an age
group × the total population in the corresponding
age group in that area. The total number of posi-
tive individuals in Taiwan was calculated as the
sum of positive individuals in each area. The total
population in each age group of an area was ob-
tained from the Department of Statistics of the
Ministry of the Interior.20 Because the population
listed by the Department of Statistics of the
Ministry of the Interior is grouped in 5-year inter-
vals, and there were few HBV or HCV carriers
younger than 20 years old, the estimated number
of HBV or HCV carriers was restricted to those
older than 20 years.
Follow-up
Screening results were mailed to subjects. Subjects
with a positive result for either HBsAg or anti-HCV
or those who had elevated AFP or ALT levels were
requested to return to the collaborating hospitals
for subsequent management.
Results
Estimated seroprevalence of HBV and 
HCV in Taiwan
From 1996 to June 2005, a total of 164,302 screen-
ings were performed. Analysis by name and birth
date revealed that 3988 persons had multiple 
examinations and 312 records had incomplete
name data (either missing surname or missing
first name). These 4300 records were excluded.
Thus, a total of 160,002 subjects were included in
the analysis. The mean age of those subjects was
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54.8 ± 15.9 years. Among them, 157,720 subjects
were ≥ 20 years old. The subsequent analyses
were based on these 157,720 subjects.
The prevalence of positive HBsAg was 17.3%
(27,210/157,720), while the prevalence of posi-
tive anti-HCV was 4.4% (6904/157,720). Among
subjects with available gender data, the HBsAg
positive rate was 21.0% (14,171/67,559) in males
and 14.0% (11,867/84,600) in females (male vs.
female, p < 0.001). The anti-HCV positive rate was
4.5% (3029/67,559) in males and 4.3% (3611/
84,600) in females (male vs. female, p = 0.0412).
Geographic variation in seroprevalence of
HBV and HCV
Geographic variation in HBV and HCV seropreva-
lence were analyzed in the 157,451 subjects with
available data on location of residence. Because
of differences in the mean age of the screened
subjects among different cities/counties (data
not shown), age-adjusted prevalence was used to
compare seroprevalence among different cities/
counties. The age-adjusted prevalence was esti-
mated using the WHO 2000 standard popula-
tion as a standard.
As shown in Table 1, the crude seroprevalence
of HBV was around 13–25% in different cities or
counties. Analysis of age-adjusted HBV seropreva-
lence showed that Keelung City and Yilan City had
the highest HBV seroprevalence, while Penghu
County and Taitung County had the lowest HBV
seroprevalence.
As shown in Table 2, there was a wide varia-
tion in crude HCV seroprevalence, ranging from
0.4% to 10.5%. Analysis of age-adjusted HCV
seroprevalence revealed that Miaoli County had
the highest HCV prevalence, followed by Chiayi
County, Chiayi City, Yunlin County, Tainan
County, Kaohsiung City and Kaohsiung County.
Kinmen County had the lowest age-adjusted HCV
seroprevalence.
Seroprevalence of HBV and HCV 
in different age groups
To investigate trends in HBV and HCV seropreva-
lence by birth year, we arbitrarily grouped subjects
into 10-year intervals and calculated the HBsAg
and anti-HCV positive rate according to birth year.
As shown in Figure 1, subjects with birth years
1950–1969 had the highest HBsAg positive rate.
The HBsAg positive rate progressively decreased
in subjects born before 1950. In contrast to the
age trend in HBsAg positive rate, the anti-HCV
positive rate progressively increased from birth
years 1970–1983 to birth year 1919 (Figure 2).
To further delineate HCV seroprevalence in the
different age groups, we arbitrarily classified HCV
seroprevalence into four categories: ≤ 2.4%, 2.5–
4.9%, 5–10%, > 10%. As shown in Table 3, there
was no difference in the trends of progressively
increasing HCV prevalence after the age of 20 years
among the four prevalence categories.
Estimate of total carrier numbers
Due to the finding of differences in the seroposi-
tive rate in different city/counties or age groups,
we estimated the HBsAg and anti-HCV carrier
numbers based on the combined stratifications
of city/county and age groups. The estimated total
number of HBsAg carriers in the general popula-
tion > 20 years old in Taiwan was 3,067,307, while
the estimated total number of anti-HCV positive
carriers was 423,283.
Discussion
This study estimated that in Taiwan as a whole, the
prevalence of positive HBsAg was 17.3%, while
the prevalence of positive anti-HCV was 4.4%.
The HBsAg positive rate was similar to that re-
ported 18 years ago.4 This finding was not sur-
prising because the study subjects were restricted
to persons older than 20 years with birth year 
before 1984. As universal HBV immunization
was started in Taiwan in 1984,8 subjects older
than 20 years comprise the unvaccinated cohort.
Previous studies have shown that the prevalence
of positive anti-HCV in the general population is
around 0.4–2.5%.1,11–13 Our current study’s anti-
HCV positive rate is slightly higher than those
described before.
HBV and HCV in Taiwan
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There were geographic variations in both HBV
and HCV seroprevalence in Taiwan. The reasons
for the geographic variations in the seroprevalence
of HBV are not known. Sampling bias may be one
of the possible explanations. For example, in
Keelung City, the HBsAg positive rate in birth years
1970–1983 was 42.9%, which was significantly
higher than the HBsAg positive rates of the same
birth years in other areas. Therefore, we cannot
rule out the possibility that the screened subjects
in Keelung might contain a certain proportion of
HBV carriers, thus leading to the higher HBV
seroprevalence in Keelung. Regarding the anti-
HCV positive rate, our study clearly showed that
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Figure 1. Birth year-adjusted seroprevalence 
of hepatitis B virus (HBV) estimated from a 
large-scale survey of free hepatitis screening 
participants in Taiwan.
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there were wide differences in HCV seropreva-
lence between different areas. Previous studies
have shown that there are several high HCV in-
fection areas in Taiwan.21 The high HCV preva-
lent areas identified in our study are consistent
with previous findings. The HCV hyperendemic
areas might be related to the iatrogenic routes.
The local culture and medical seeking-behaviors,
such as frequent intravenous injection for minor
diseases or incomplete disinfection of medical
equipment in the past, might contribute to the
high HCV prevalence rate.16,22 However, the real
causes of the high HCV prevalence in Miaoli,
Yunlin and Chiayi, etc., remain to be investigated.
It was interesting that HBV prevalence pro-
gressively declined in subjects with birth years
before 1950 (i.e. about after 50 years old). At least
two reasons could explain this observation. First,
since the peak age of advanced HBV-related liver
diseases is 50–60 years, it is probable that some
HBV carriers had died of liver-related diseases after
50 years old. Thus, the percentage of HBsAg posi-
tivity declined. Second, it has been shown that
delayed HBsAg clearance contributes to decreased
prevalence of HBsAg.23,24 Contrary to the trend of
HBsAg, the anti-HCV positive rate progressively
increased after 20 years old, similar to that found
previously in a smaller scale study.22 The progres-
sive increase in HCV seroprevalence with increased
age were found in different areas with different
rates of HCV seroprevalence. This observation is
also compatible with the concept that HCV infec-
tion is acquired in adulthood.
In addition to seroprevalence, one important
issue for controlling viral hepatitis is disease bur-
den. Thus, we estimated the patient numbers based
on our results. Because there were variations in
seroprevalence among townships, the best way
to estimate total patient numbers was to use the
township-specific seroprevalence. Unfortunately,
we did not screen every township of each county
or city. Therefore, we did not have detailed town-
ship-specific seroprevalence. So, we used city/
county seroprevalence instead. In the general
population older than 20 years, we estimated a
total of 3,067,307 HBsAg carriers, and a total of
423,283 anti-HCV positive patients. These data
could help us with resource allocation in control-
ling viral hepatitis in Taiwan.
However, there were drawbacks to our current
study. Since the open screening program relied on
subjects volunteering to come forward of their
own volition, the screened population might not
represent the true general population in Taiwan.
It is possible that more sick than healthy people
participated, leading to an overestimation of 
the prevalence of HBsAg and anti-HCV. Neverthe-
less, our data constitute a useful reference for the 
prevention and treatment of viral hepatitis in
Taiwan.
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Table 3. Seroprevalence of hepatitis C virus 
(HCV) according to age and different
prevalence rates
HCV prevalence (%)
Age group (yr)
≤ 2.4 2.5–4.9 5–10 > 10
20–24 0 0.8 0.4 3.1
25–29 0.3 0.7 1.0 1.6
30–34 0.5 1.2 1.9 4.1
35–39 0.7 1.7 1.5 3.9
40–44 1.1 1.6 2.1 5.4
45–49 1.3 2.8 3.3 7.2
50–54 1.8 4.0 5.8 8.9
55–59 2.0 4.5 7.6 12.4
60–64 2.4 5.9 8.4 12.7
65–69 2.6 7.1 12.3 9.6
70–74 3.4 7.9 14.2 14.8
75–79 3.9 8.3 14.9 19.2
80–84 4.2 6.6 13.5 20.6
85–89 4.1 6.8 16.4 17.8
> 90 3.8 8.0 17.9 16.7
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